Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 218

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 218
---
, 2025, along with the status in other jurisdictions. All patents are utility patents. We have additional patent applications that have not yet published as of June 30, 2025. BillionToOne Patent Portfolio

| Patent 
 Family |     | Patent Name                                                                         |     | Summary                                                                                                                                                                                                                                             |     | U.S. Patent 
      Number |     | U.S. Exp. 
 Date      |     | Other Jurisdictions |
| P01    |     | Dilution Tagging for Quantification of Biological Targets                           |     | Method for accurate determination of biological target abundance that can include generating a first set of molecules associated with a target sequence that includes dilution tags associated                                                      
 with a relative concentration profile; generating a second set of molecules including dilution tags; generating a dilution tagged mixture; amplifying the dilution tagged targets; generating a modified dilution tagged mixture from the amplified 
 subsets; determining, for the biological sample, a count of the distinct molecules including the target sequence.                                                                                                                                   |     |  12,071,651 |     | 3-19-2041 |     | Issued/Allowed: CA  
 Pending: CN, EU, HK |
| P02    |     | Target-Associated Molecules for Characterization Associated with Biological Targets |     | A method and/or system for facilitating characterization of one or more conditions that can include: generating a set of target-associated molecules; generating a                                                                                  
 reference-associated set of molecules; facilitating generation of a spike-in mixture; determining abundance metrics based on an analysis of the spike-in mixture; and                                                                               
 facilitating the characterization of the conditions based on the abundance metrics                                                                                                                                                                  |     |  11,646,100 |     | 3-5-2042  |     | Issued/Allowed: CA  
 Pending: CN, EU, HK |

165

| Patent 
 Family |     | Patent Name                                                                                                                        |     | Summary                                                                                                                                                                                                                                                                                                                                                                                                        |     | U.S. Patent 
      Number |     | U.S. Exp. 
 Date      |     | Other Jurisdictions                                                                           |
| P03    |     | Sequencing Output Determination and Analysis with Target-Associated Molecules in Quantification Associated with Biological Targets |     | A method and/or system for generating a set of target-associated molecules (e.g., spike-in molecules) associated with biological                                                                                                                                                                                                                                                                               
 targets; generating spike-in mixtures based on processing the set of target-associated molecules with samples including the biological targets; performing Sanger